Literature DB >> 25748953

Development of nodular regenerative hyperplasia (NRH) with portal hypertension following the administration of oxaliplatin for the recurrence of colon cancer.

Hiroaki Takaya1, Hideto Kawaratani, Keisuke Nakanishi, Shinya Takeyama, Chie Morioka, Masayoshi Sawai, Masahisa Toyohara, Masao Fujimoto, Hitoshi Yoshiji, Junichi Yamao, Hiroshi Fukui.   

Abstract

Nodular regenerative hyperplasia (NRH) is associated with autoimmune and hematologic diseases and may lead to portal hypertension. We herein report a case of NRH diagnosed based on a liver biopsy. A 63-year-old woman developed esophageal varices and splenomegaly. She had undergone surgery for transverse colon cancer 24 years earlier and received systemic chemotherapy (FOLFOX4 including oxaliplatin) to treat lymph node metastasis 21 years after the operation. The present liver biopsy confirmed NRH, and, after two years, she received endoscopic injection sclerotherapy. Oxaliplatin was suspected to be the causative agent of NRH in this case. Therefore, physicians must consider the possibility of NRH in patients who receive chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25748953     DOI: 10.2169/internalmedicine.54.2461

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  2 in total

1.  Nodular regenerative hyperplasia rarely leads to liver transplantation: A 20-year cohort study in all Dutch liver transplant units.

Authors:  Berrie Meijer; Melek Simsek; Hans Blokzijl; Robert A de Man; Minneke J Coenraad; Gerard Dijkstra; Carin Mj van Nieuwkerk; Chris Jj Mulder; Nanne Kh de Boer
Journal:  United European Gastroenterol J       Date:  2016-11-16       Impact factor: 4.623

Review 2.  Porto-Sinusoidal Vascular Disease Associated to Oxaliplatin: An Entity to Think about It.

Authors:  Angela Puente; Jose Ignacio Fortea; Carmen Del Pozo; Patricia Huelin; Maria Luisa Cagigal; Marina Serrano; Joaquin Cabezas; Maria Teresa Arias Loste; Paula Iruzubieta; Antonio Cuadrado; Susana Llerena; Carlos Lopez; Emilio Fábrega; Javier Crespo
Journal:  Cells       Date:  2019-11-24       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.